Cory Freedland is a Partner at Samsara and joined the firm in 2017 when the fund was launched. He currently serves of the board of directors of multiple Samsara portfolio companies including Bionic Sight, Alpha-9 Oncology, Nura Bio, Neurogene (NGNE), and OrsoBio.
Prior to Samsara, Cory was a Principal at Sofinnova Ventures where he focused on biopharmaceutical investments. Cory played a central role in Sofinnova’s investments in BioClin Therapeutics, Civitas (acquired by Acorda), Principia Biopharma, Spark Therapeutics (ONCE, acquired by Roche), Ziarco (acquired by Novartis), and ZS Pharma (ZSPH; acquired by AstraZeneca). Prior to Sofinnova, Cory was a Principal at Novo A/S.
Cory received a B.A. in Psychology and Religious Studies from Connecticut College, a PhD in Pharmacology from Wake Forest University School of Medicine, and an MBA from the Kellogg School of Management.